Sulindac metabolites decrease cerebrovascular malformations in CCM3-knockout mice
Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani, Luca Bravi, Noemi Rudini, Roberto Cuttano, Costanza Giampietro, Luigi Maddaluno, Luca Ferrarini, Ralf H Adams, Monica Corada, Gwenola Boulday, Elizabeth Tournier-Lasserve, Elisabetta Dejana, Maria Grazia Lampugnani
Abstract
Cerebral cavernous malformation (CCM) is a disease of the central nervous system causing hemorrhage-prone multiple lumen vascular malformations and very severe neurological consequences. At present, the only recommended treatment of CCM is surgical. Because surgery is often not applicable, pharmacological treatment would be highly desirable. We describe here a murine model of the disease that develops after endothelial-cell-selective ablation of the CCM3 gene. We report an early, cell-autonomous, Wnt-receptor-independent stimulation of β-catenin transcription activity in CCM3-deficient endothelial cells both in vitro and in vivo and a triggering of a β-catenin-driven transcription program that leads to endothelial-to-mesenchymal transition. TGF-β/BMP signaling is then required for the progression of the disease. We also found that the anti-inflammatory drugs sulindac sulfide and sulindac sulfone, which attenuate β-catenin transcription activity, reduce vascular malformations in endothelial CCM3-deficient mice. This study opens previously unidentified perspectives for an effective pharmacological therapy of intracranial vascular cavernomas.
Keywords: cerebral cavernous malformation; endothelial cells; sulindac metabolites; vascular pathology; β-catenin.
Conflict of interest statement
The authors declare no conflict of interest.
Figures





Source: PubMed
다가오는 임상 시험
-
Shirley Ryan AbilityLabKiwanis Neurological Research Foundation모병
-
University of ChicagoNational Heart, Lung, and Blood Institute (NHLBI)아직 모집하지 않음
-
Fundacion para la Investigacion Biomedica del Hospital...Hospital Universitario La Fe모병
-
Lumetry Diagnostics GmbHKarl Landsteiner Institute for Lung Research and Pneumological Oncology; Klinik Floridsdorf아직 모집하지 않음
-
Beijing Suncadia Pharmaceuticals Co., Ltd모병
-
Xiangya Hospital of Central South University아직 모집하지 않음
-
Halic University아직 모집하지 않음수면의 질 | 식이 중재 | 인지된 스트레스 | 브레인 포그터키 (Türkiye)
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University아직 모집하지 않음전이성 유방암 | 호르몬 수용체 양성 유방암 | HER2-낮은 유방암중국
-
The 108 Military Central HospitalVietnam Military Medical University; Thanh Phuong Co., Ltd아직 모집하지 않음
-
University Hospital, Montpellier아직 모집하지 않음
-
Kasr El Aini Hospital모병